Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Rating of “Buy” from Brokerages

Capricor Therapeutics Inc (NASDAQ:CAPR) has earned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $34.50.

A number of research firms recently weighed in on CAPR. Piper Sandler assumed coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, November 14th. Oppenheimer restated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Cantor Fitzgerald raised their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Finally, Maxim Group boosted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th.

Institutional Investors Weigh In On Capricor Therapeutics

Large investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in Capricor Therapeutics in the 3rd quarter worth about $458,000. Barclays PLC increased its stake in shares of Capricor Therapeutics by 106.6% in the third quarter. Barclays PLC now owns 36,296 shares of the biotechnology company’s stock worth $552,000 after purchasing an additional 18,724 shares in the last quarter. Sphera Funds Management LTD. bought a new stake in shares of Capricor Therapeutics in the third quarter valued at approximately $938,000. State Street Corp lifted its stake in shares of Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after buying an additional 111,291 shares in the last quarter. Finally, Sassicaia Capital Advisers LLC bought a new position in Capricor Therapeutics in the 3rd quarter worth approximately $192,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Down 0.8 %

CAPR opened at $14.01 on Thursday. The company has a fifty day moving average price of $17.68 and a two-hundred day moving average price of $10.46. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The company has a market cap of $637.03 million, a P/E ratio of -13.22 and a beta of 3.98.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.